Mandate

Vinge advises on division of Creades

January 24, 2013

On the initiative of the majority shareholders, Bioinvestor and Pan Capital, it is proposed that Creades (NASDAQ OMX First North) will be divided into two companies pursuant to a squeeze out procedure whereby 30 per cent of Creades’ net worth will be transferred to a new, unlisted company, Sedarec, which will be distributed to the shareholders in the manner desired by them. Pan Capital will become the majority shareholder in Sedarec which, following completion of the squeeze out procedure, will be liquidated under Pan Capital’s management, whereas Creades, with Bioinvestor as its majority shareholder, will continue its long-term strategy.

Vinge team advising Creades primarily consisted of partner Erik Sjöman and associate Jo-Anna Nordström.

Related

Vinge has advised Vimian Group AB in connection with its uplisting to Nasdaq Stockholm

Vinge has advised Vimian Group AB (publ) in connection with its list change from Nasdaq First North Growth Market to Nasdaq Stockholm’s main market, Large cap. The prospectus was published on 21 March 2025 and the trading on Nasdaq Stockholm commenced on 28 March 2025.
March 28, 2025

Vinge advises Tribune Therapeutics in conjunction with financing round

Vinge advises Tribune Therapeutics, a Swedish biotechnology company focused on developing therapies for fibrotic diseases, in raising 23 MEUR. The financing round includes the previous investors HealthCap, Novo Holding and Innovestor, in addition to the new investors LifeArc Ventures, Industrifonden and Investinor.
March 26, 2025

Vinge advises Dignitana on the public offer from Paxman

Paxman AB (publ) has announced a public offer to the shareholders of Dignitana AB. The total value of the offer is approximately SEK 153 million.
March 24, 2025